Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects

por Davidson, Antonia, Brimhall, Darin, Kay, Jonathan, Keystone, Edward, Lee, Sang Joon, Kim, Sung Hyun, Bae, Yun Ju, Choi, Eun Jin, Furst, Daniel E.
Publicado 2021

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

por Park, Won, Yoo, Dae Hyun, Miranda, Pedro, Brzosko, Marek, Wiland, Piotr, Gutierrez-Ureña, Sergio, Mikazane, Helena, Lee, Yeon-Ah, Smiyan, Svitlana, Lim, Mie-Jin, Kadinov, Vladimir, Abud-Mendoza, Carlos, Kim, HoUng, Lee, Sang Joon, Bae, YunJu, Kim, SuYeon, Braun, Jürgen
Publicado 2017

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

por Kay, Jonathan, Jaworski, Janusz, Wojciechowski, Rafal, Wiland, Piotr, Dudek, Anna, Krogulec, Marek, Jeka, Slawomir, Zielinska, Agnieszka, Trefler, Jakub, Bartnicka-Maslowska, Katarzyna, Krajewska-Wlodarczyk, Magdalena, Klimiuk, Piotr A., Lee, Sang Joon, Bae, Yun Ju, Yang, Go Eun, Yoo, Jae Kyoung, Furst, Daniel E., Keystone, Edward
Publicado 2021

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

por Furst, Daniel E, Jaworski, Janusz, Wojciechowski, Rafal, Wiland, Piotr, Dudek, Anna, Krogulec, Marek, Jeka, Slawomir, Zielinska, Agnieszka, Trefler, Jakub, Bartnicka-Maslowska, Katarzyna, Krajewska-Wlodarczyk, Magdalena, Klimiuk, Piotr A, Lee, Sang Joon, Kim, Sung Hyun, Bae, Yun Ju, Yang, Go Eun, Yoo, Jae Kyoung, Kay, Jonathan, Keystone, Edward
Publicado 2021

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

por Shim, Seung Cheol, Božić-Majstorović, Ljubinka, Berrocal Kasay, Alfredo, El-Khouri, Elias Chalouhi, Irazoque-Palazuelos, Fedra, Cons Molina, Francisco Fidencio, Medina-Rodriguez, Francisco G, Miranda, Pedro, Shesternya, Pavel, Chavez-Corrales, Jose, Wiland, Piotr, Jeka, Slawomir, Garmish, Olena, Hrycaj, Pawel, Fomina, Natalia, Park, Won, Suh, Chang-Hee, Lee, Sang Joon, Lee, Sung Young, Bae, Yun Ju, Yoo, Dae Hyun
Publicado 2019

Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects

por Yu, Kyung‐Sang, Jang, In‐Jin, Lim, Hyeong‐Seok, Hong, Jang Hee, Kim, Min‐Gul, Park, Min Kyu, Cho, Doo‐Yeoun, Park, Min Soo, Chung, Jae Yong, Ghim, Jong‐Lyul, Lee, SeungHwan, Yoon, Seok Kyu, Kwon, In Sun, Lee, Sang Joon, Kim, Sung Hyun, Bae, Yun Ju, Cha, Jung Bin, Furst, Daniel E., Keystone, Edward, Kay, Jonathan
Publicado 2021

546. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial

por Ison, Michael G, Kim, Jin Yong, Sandulescu, Oana, Preotescu, Liliana-Lucia, Martinez, Norma Erendira Rivera, Dobryanska, Marta, Birlutiu, Victoria, Miftode, Egidia Gabriela, Gaibu, Natalia, Caliman-Sturdza, Olga Adriana, Florescu, Simin-Aysel, Streinu-Cercel, Anca, Lee, Sang Joon, Kim, Sung Hyun, Chang, Il Sung, Bae, Yun Ju, Suh, Jee Hye, Kim, Mi Rim, Chung, Da Re, Kim, Sun Jung, Lee, Seul Gi, Park, Ga Hee, Eom, Joong Sik
Publicado 2021

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019

por Kim, Jin Yong, Săndulescu, Oana, Preotescu, Liliana-Lucia, Rivera-Martínez, Norma E, Dobryanska, Marta, Birlutiu, Victoria, Miftode, Egidia G, Gaibu, Natalia, Caliman-Sturdza, Olga, Florescu, Simin-Aysel, Shi, Hye Jin, Streinu-Cercel, Anca, Streinu-Cercel, Adrian, Lee, Sang Joon, Kim, Sung Hyun, Chang, Ilsung, Bae, Yun Ju, Suh, Jee Hye, Chung, Da Rae, Kim, Sun Jung, Kim, Mi Rim, Lee, Seul Gi, Park, Gahee, Eom, Joong Sik
Publicado 2022